Compare RMR & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMR | ALDX |
|---|---|---|
| Founded | 1986 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 293.0M |
| IPO Year | N/A | 2014 |
| Metric | RMR | ALDX |
|---|---|---|
| Price | $15.83 | $4.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 199.9K | ★ 928.5K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | ★ 11.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $196,824,000.00 | N/A |
| Revenue This Year | $301.43 | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | $15.26 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.48 | $1.14 |
| 52 Week High | $22.48 | $7.20 |
| Indicator | RMR | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 39.04 |
| Support Level | $14.85 | $4.67 |
| Resistance Level | $15.77 | $5.04 |
| Average True Range (ATR) | 0.36 | 0.29 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 86.22 | 3.42 |
The RMR Group Inc is a holding company that conducts its business through its subsidiary, which is an alternative asset management company that invests in real estate and manages real estate-related businesses. Its business consists of providing management services to publicly owned real estate investment trusts, or REITs, and real estate-related operating companies. It also provides management services to real estate securities mutual funds and commercial real estate finance companies. The company's operating segment is RMR LLC and All Other Operations. The RMR Group derives its revenue from providing business and property management services as well as advisory and other services.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.